This analysis revealed that TRIP13 was expressed in T–cell lymphoma (T8ML-1, MJ, HH), T–cell leukemia (JURKAT, MOLT4, MOT, SUPT1, LOUCY, CCRF-CEM, DND-41), B–cell lymphoma (RAJI), B-cell leukemia (MEC-1, MEC-2), and myeloid leukemia (K562, CTV-1) cell lines (Figure 6C, Figures S21 and S22). Here, TRIP13 is linked to B-cell non-Hodgkin lymphoma.